Dimitris Voliotis, Chief Medical Officer of Radiopharm Theranostics Ltd (NASDAQ:RADX), filed a Form 4 on October 27, 2026, disclosing the acquisition of three tranches of options to purchase Ordinary Shares, all dated October 19, 2026.

Key Highlights

  • Reporting person: Dimitris Voliotis, Chief Medical Officer of Radiopharm Theranostics Ltd
  • Transaction date: October 19, 2026, covering three separate option grants each coded as acquired (A)
  • Total options acquired: 30,887,000 options (10,295,667 + 10,295,667 + 10,295,666) to purchase Ordinary Shares
  • Exercise price: $0.021 per option, denominated in Australian dollars according to the filing
  • Expiration date: July 1, 2031 for all three tranches
  • Vesting dates: The three tranches become exercisable on July 1, 2027; July 1, 2028; and July 1, 2029, respectively
  • Price paid: $0.00 per derivative security for each tranche; all options are held directly; no non-derivative securities are beneficially owned

Voliotis Option Grant Details: Three Tranches, Staggered Vesting Through 2029

According to the filing, Voliotis received three tranches of options, each classified as an "Option (Right to buy)" with a conversion or exercise price of $0.021 (Australian dollars, as noted in the filing's explanation of responses). All three transactions carry a transaction code of A, indicating acquisition. The underlying security for all tranches is Ordinary Shares of Radiopharm Theranostics Ltd, traded on NASDAQ:RADX.

The first tranche covers 10,295,667 options, exercisable beginning July 1, 2027, and expiring July 1, 2031. The second tranche also covers 10,295,667 options, with an exercise date of July 1, 2028, and the same expiration. The third tranche covers 10,295,666 options, exercisable beginning July 1, 2029, also expiring July 1, 2031. All three tranches are held directly by Voliotis, and the price of each derivative security at acquisition was reported as $0.00. The filing states that there are no non-derivative securities beneficially owned by the reporting person following these transactions.

The filing was signed by Dimitris Voliotis on October 27, 2026. No amendment date is listed, indicating this is an original filing. The filing does not check the box indicating a Rule 10b5-1(c) plan.

What Was Disclosed

Radiopharm Theranostics Ltd's Chief Medical Officer, Dimitris Voliotis, disclosed the acquisition of 30,887,000 options to buy Ordinary Shares at an exercise price of $0.021 (Australian dollars), with vesting across three annual dates from 2027 to 2029, all expiring July 1, 2031.